## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($212.35)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Did IQVIAâ€™s (IQV) Debt Refinancing and Lower SOFR Costs Just Shift Its Investment Narrative?**
- Source: Simply Wall Street | 20251214T180826 | Somewhat-Bullish | Relevance: 100%
- IQVIA Holdings recently refinanced its credit facilities, simplifying its capital structure and reducing borrowing costs by eliminating the SOFR credit spread adjustment for some US dollar borrowings. This move aims to free up cash flow for its global operations and slightly eases concerns about high leverage, impacting its investment narrative. Investors should monitor how IQVIA converts its R&D Solutions backlog into profit growth amidst competitive market conditions.

**2. Lazard Asset Management LLC Acquires 107,500 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251214T134208 | Bullish | Relevance: 100%
- Lazard Asset Management LLC increased its stake in IQVIA Holdings Inc. by 6.1%, now owning 1,866,537 shares valued at approximately $294.1 million. The medical research company recently reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating from analysts with an average price target of $241.82.

**3. Bellevue Group AG Sells 27,368 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251213T093048 | Neutral | Relevance: 98%
- Bellevue Group AG has significantly reduced its stake in IQVIA Holdings Inc. by selling 27,368 shares, decreasing its holdings by 44.8%. Despite this, other institutional investors have either increased their positions or maintained substantial holdings in IQVIA, indicating mixed sentiment. Analyst ratings for IQVIA are generally positive, with an average rating of "Moderate Buy" and an average target price of $241.82.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $5.8M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +4.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.1B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.3 |
| Current P/E | 18.8 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.6% to 0.0% (+4.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.0pp (needs >4.0% for momentum thesis). MRS_5 at 2.0% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.23x) but short-term weakness (below SMA20). MACD histogram bearish (-1.02), momentum weakening. RSI neutral at 53. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.01% (CS: 35) | Neutral |
| RSI_14 | 53.0 | Neutral |
| MACD Histogram | -1.02 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.232x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $223.63
- **Stop Loss:** $212.35 (5.0% risk)
- **Target:** $246.19 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $23,704.78
- **Portfolio %:** 23.70%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*